Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDAH1 | O94760 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | RRM1 | P23921 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 4/20 | 0.35 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16093029 | 1.00 | DDAH1 (0.41) | DDAH1DPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL22281181 | 0.86 | DDAH1 (0.43) | DDAH1DPP7ACHEBRD4MEN1 | |
| SCHEMBL22281180 | 0.84 | DDAH1 (0.57) | DDAH1DPP7MEN1GAAKMT2A | |
| SCHEMBL7194971 | 0.84 | DDAH1 (0.57) | DDAH1DPP7MEN1GAAKMT2A | |
| SCHEMBL28297586 | 0.84 | DDAH1 (0.57) | DDAH1DPP7MEN1GAAKMT2A | |
| SCHEMBL22878134 | 0.82 | DDAH1 (0.39) | DDAH1DPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL9966613 | 0.80 | DDAH1 (0.52) | DDAH1DPP7ANPEPERN1 | |
| SCHEMBL458808 | 0.80 | DDAH1 (0.52) | DDAH1DPP7ANPEPERN1 | |
| SCHEMBL30310821 | 0.80 | DDAH1 (0.43) | DDAH1DPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL30033086 | 0.80 | DDAH1 (0.52) | DDAH1DPP7ANPEPERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150044693-A1 | Levetiracetam Immunoassays | ARK DIAGNOSTICS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20120190047-A1 | Levetiracetam Immunoassays | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2012-07-26 | — | — | US | disclosed |
| US-8168756-B2 | Levetiracetam immunoassays | ARK DIAGNOSTICS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100173427-A1 | LEVETIRACETAM IMMUNOASSAYS | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190047-A1 | Levetiracetam Immunoassays | GABRG1, GABRA6, LY96 | DDAH1 2803/4885DPP7 1276/4885GNAI3 777/4885 |
| US-20100173427-A1 | LEVETIRACETAM IMMUNOASSAYS | GABRG1, GABRA6, LY96 | DDAH1 2803/4885DPP7 1276/4885GNAI3 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.